- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-ITB7/ ITGB7 monoclonal antibody
Anti-ITB7/ ITGB7 antibody for FACS & in-vivo assay
Go to ITGB7/ITGB7 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T14065-Ab-1/ GM-Tg-hg-T14065-Ab-2 | Anti-Human ITGB7 monoclonal antibody | Human |
| GM-Tg-rg-T14065-Ab-1/ GM-Tg-rg-T14065-Ab-2 | Anti-Rat ITGB7 monoclonal antibody | Rat |
| GM-Tg-mg-T14065-Ab-1/ GM-Tg-mg-T14065-Ab-2 | Anti-Mouse ITGB7 monoclonal antibody | Mouse |
| GM-Tg-cynog-T14065-Ab-1/ GM-Tg-cynog-T14065-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ITGB7 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T14065-Ab-1/ GM-Tg-felg-T14065-Ab-2 | Anti-Feline ITGB7 monoclonal antibody | Feline |
| GM-Tg-cang-T14065-Ab-1/ GM-Tg-cang-T14065-Ab-2 | Anti-Canine ITGB7 monoclonal antibody | Canine |
| GM-Tg-bovg-T14065-Ab-1/ GM-Tg-bovg-T14065-Ab-2 | Anti-Bovine ITGB7 monoclonal antibody | Bovine |
| GM-Tg-equg-T14065-Ab-1/ GM-Tg-equg-T14065-Ab-2 | Anti-Equine ITGB7 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T14065-Ab-1/ GM-Tg-hg-T14065-Ab-2; GM-Tg-rg-T14065-Ab-1/ GM-Tg-rg-T14065-Ab-2; GM-Tg-mg-T14065-Ab-1/ GM-Tg-mg-T14065-Ab-2; GM-Tg-cynog-T14065-Ab-1/ GM-Tg-cynog-T14065-Ab-2; GM-Tg-felg-T14065-Ab-1/ GM-Tg-felg-T14065-Ab-2; GM-Tg-cang-T14065-Ab-1/ GM-Tg-cang-T14065-Ab-2; GM-Tg-bovg-T14065-Ab-1/ GM-Tg-bovg-T14065-Ab-2; GM-Tg-equg-T14065-Ab-1/ GM-Tg-equg-T14065-Ab-2 |
| Products Name | Anti-ITGB7 monoclonal antibody |
| Format | mab |
| Target Name | ITGB7 |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-ITGB7 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation | Lyophilized from sterile PBS, PH 7.4 |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Biosimilar | GMP-Bios-ab-616 | Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody |
| Biosimilar | GMP-Bios-ab-200 | Pre-Made Etrolizumab biosimilar, Whole Mab: Anti-ITGA4;ITGB7;ITGAE;ITGB7 therapeutic antibody |
| Target Antigen | Products Developing | Multi-species ITB7/ ITGB7 VLP (virus-like particle) (Products Developing) |
| ORF Viral Vector | vGMLV000442 | human ITGB7 Lentivirus particle |
| ORF Viral Vector | pGMLV000442 | human ITGB7 Lentivirus plasmid |
Target information
| Target ID | GM-T14065 |
| Target Name | ITGB7 |
| Gene ID | 3695,16421,25713,699405,477598,101099982,514031,100063747 |
| Gene Symbol and Synonyms | ITGB7,Ly69 |
| Uniprot Accession | P26010 |
| Uniprot Entry Name | ITB7_HUMAN |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, INN Index |
| Disease | N/A |
| Gene Ensembl | ENSG00000139626 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: ITGB7, gene name: ITGB7, also named as . This gene encodes a protein that is a member of the integrin superfamily. Members of this family are adhesion receptors that function in signaling from the extracellular matrix to the cell. Integrins are heterodimeric integral membrane proteins composed of an alpha chain and a beta chain. The encoded protein forms dimers with an alpha4 chain or an alphaE chain and plays a role in leukocyte adhesion. Dimerization with alpha4 forms a homing receptor for migration of lymphocytes to the intestinal mucosa and Peyer's patches. Dimerization with alphaE permits binding to the ligand epithelial cadherin, a calcium-dependent adhesion molecule. Alternate splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. [provided by RefSeq, Sep 2013].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
